Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
December 16, 2016
-
ORGANIZATION JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
-
REGULATORY PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
-
REGULATORY MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
-
REGULATORY Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
-
BUSINESS Aspen Japan Starting on Right Foot on AG Biz: GSK Japan President
December 13, 2016
-
REGULATORY Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
-
REGULATORY (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
-
REGULATORY Govt Eyes “Bailout Measures” for Products with Small NHI-Market Price Gaps in Annual Revision Plan
December 9, 2016
-
REGULATORY Shiozaki, Govt Panel Agree on Annual Price Reviews, but Scope of Drugs Still Unclear
December 8, 2016
-
BUSINESS Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
-
REGULATORY LDP Tax Panel OKs Refit of R&D Tax Credit System in FY2017
December 7, 2016
-
BUSINESS Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
-
ORGANIZATION Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
-
BUSINESS Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
December 6, 2016
-
REGULATORY PM Abe’s Council to Discuss Annual Drug Price Revisions Again on Dec. 7
December 5, 2016
-
INTERVIEW Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary
December 2, 2016
-
REGULATORY Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
-
REGULATORY Chuikyo to Discuss “Price-Setting Including NHI Price Increases” Using Cost-Effective Assessments
December 1, 2016
-
REGULATORY “Outright” or “Partial”? Annual Revision Debate Rekindled in a Rush to Revamp Drug Pricing
November 30, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…